Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
Mineralys Therapeutics (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focusing on developing medicines for hypertension, chronic kidney disease (CKD), and aldosterone-related disorders, has announced its plan to release second quarter 2024 financial results on Tuesday, August 13, 2024, after market close. The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results. Interested parties can access the call via domestic (1-877-407-9127) or international (1-201-689-8574) phone numbers, or through a webcast link available on the company's Investor Relations webpage.
Mineralys Therapeutics (NASDAQ: MLYS), un'azienda biofarmaceutica in fase clinica che si concentra sullo sviluppo di medicinali per l'ipertensione, la malattia renale cronica (CKD) e i disturbi correlati all'aldosterone, ha annunciato il suo piano di pubblicare i risultati finanziari del secondo trimestre 2024 il martedì 13 agosto 2024, dopo la chiusura del mercato. L'azienda ospiterà una teleconferenza e un webcast alle 16:30 ET dello stesso giorno per discutere i risultati. Le parti interessate possono accedere alla chiamata tramite i numeri telefonici nazionali (1-877-407-9127) o internazionali (1-201-689-8574), oppure attraverso un link per il webcast disponibile sulla pagina delle Relazioni con gli Investitori dell'azienda.
Mineralys Therapeutics (NASDAQ: MLYS), una empresa biofarmacéutica en etapa clínica centrada en el desarrollo de medicamentos para la hipertensión, la enfermedad renal crónica (ERC) y trastornos relacionados con la aldosterona, ha anunciado su plan para publicar los resultados financieros del segundo trimestre de 2024 el martes 13 de agosto de 2024, después del cierre del mercado. La compañía realizará una llamada de conferencia y un webcast a las 4:30 p.m. ET el mismo día para discutir los resultados. Las partes interesadas pueden acceder a la llamada a través de los números de teléfono nacionales (1-877-407-9127) o internacionales (1-201-689-8574), o a través de un enlace de webcast disponible en la página de Relaciones con Inversionistas de la empresa.
미네랄리스를 치료제 (NASDAQ: MLYS)는 고혈압, 만성 신장 질환 (CKD), 및 알도스테론 관련 장애를 위한 약물 개발에 집중하는 임상 단계의 생명공학 회사로, 2024년 2분기 재무 결과를 2024년 8월 13일 화요일 마감 이후 발표할 계획을 발표했습니다. 회사는 같은 날 오후 4시 30분 ET에 결과를 논의하기 위한 컨퍼런스 콜 및 웹캐스트를 개최할 예정입니다. 관심 있는 분들은 국내 전화 (1-877-407-9127) 또는 국제 전화 (1-201-689-8574)를 통해 또는 회사의 투자자 관계 웹페이지에 제공된 웹캐스트 링크를 통해 전화를 이용할 수 있습니다.
Mineralys Therapeutics (NASDAQ: MLYS), une entreprise biopharmaceutique en phase clinique axée sur le développement de médicaments pour l'hypertension, les maladies rénales chroniques (ERC) et les troubles liés à l'aldostérone, a annoncé son intention de publier les résultats financiers du deuxième trimestre 2024 le mardi 13 août 2024, après la clôture du marché. L'entreprise organisera un appel conférence et un webcast à 16h30 ET le même jour pour discuter des résultats. Les parties intéressées peuvent accéder à l'appel via les numéros de téléphone nationaux (1-877-407-9127) ou internationaux (1-201-689-8574), ou via un lien de webcast disponible sur la page des Relations Investisseurs de l'entreprise.
Mineralys Therapeutics (NASDAQ: MLYS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Medikamenten gegen Hypertonie, chronische Nierenerkrankungen (CKD) und aldosteronbezogene Störungen konzentriert, hat seinen Plan angekündigt, die Finanzergebnisse für das zweite Quartal 2024 am Dienstag, den 13. August 2024, nach Börsenschluss zu veröffentlichen. Das Unternehmen wird an demselben Tag um 16:30 Uhr ET eine Telefonkonferenz und einen Webcast veranstalten, um die Ergebnisse zu besprechen. Interessierte Parteien können über die inländischen Telefonnummern (1-877-407-9127) oder die internationalen Telefonnummern (1-201-689-8574) auf den Anruf zugreifen oder über einen auf der Investor-Relations-Webseite des Unternehmens verfügbaren Webcast-Link teilnehmen.
- None.
- None.
RADNOR, Pa., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the second quarter ended June 30, 2024, after the financial markets close on Tuesday, August 13, 2024.
| Tuesday, August 13th @ 4:30 p.m. ET | |
| Domestic: | 1-877-407-9127 |
| International: | 1-201-689-8574 |
| Webcast: | Link |
A live webcast of the conference call may be found here or on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.
About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension and CKD. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.
Contact:
Investor Relations
investorrelations@mineralystx.com
Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com
FAQ
When will Mineralys Therapeutics (MLYS) release its Q2 2024 financial results?
What time is Mineralys Therapeutics' (MLYS) Q2 2024 earnings call scheduled for?
How can investors access Mineralys Therapeutics' (MLYS) Q2 2024 earnings call?
What are the main therapeutic areas Mineralys Therapeutics (MLYS) focuses on?
